Plasmid Name
pHC-IgG1-ADE
Mutation Set
G236A / S239D / I332E
Selection Marker
Ampicillin
Promoter
CMV
Fc Engineering Overview
The human IgG1 (ADE) Fc variant is a multi-domain engineered variant designed to simultaneously optimize FcγRIIIa binding for NK cell-mediated ADCC and maximize the FcγRIIa/FcγRIIb activation ratio for potent macrophage-mediated ADCP. By combining lower hinge and CH2 domain mutations, it provides high dual effector activation while preserving wild-type complement (CDC) activity.
Functional Profile
| Property | Effect |
|---|---|
| FcγRIIIa binding (V158 & F158) | Strongly Increased ↑↑↑ (∼30–50× affinity boost) |
| FcγRIIa binding (H131 & R131) | Strongly Increased ↑↑ (A/I activation ratio optimized) |
| FcγRIIb binding (Inhibitory) | Lower relative engagement vs. FcγRIIa |
| ADCC | Potently Enhanced ↑↑↑ |
| ADCP (Macrophage Phagocytosis) | Potently Enhanced ↑↑↑ |
| CDC | WT Baseline / Preserved |
| FcRn binding & half-life | Normal / WT Baseline |
| Effector Potency | High-Potency Dual ADCC/ADCP Enhancer |
Mechanism of Action
The ADE Fc variant combines three synergistic amino acid substitutions across the lower hinge and CH2 domain:
- G236A (Lower Hinge): Restructures backbone conformational flexibility at the hinge-CH2 junction, specifically enhancing affinity for activating FcγRIIa (CD32a) while minimizing engagement with inhibitory FcγRIIb (CD32b).
- S239D (CH2 Domain): Introduces a negative charge that establishes favorable electrostatic complementarity with positively charged surface residues on FcγRIIIa (CD16a).
- I332E (CH2 Domain): Adds a second negatively charged carboxyl group at a critical receptor contact interface, further locking in high-affinity engagement.
Phenotypic Effects
- Strong enhancement of NK cell recruitment and ADCC target cell lysis.
- Optimized FcγRIIa/FcγRIIb binding ratio leading to superior macrophage phagocytosis (ADCP).
- High functional potency across all patient FcγRIIIa genotypes (V/V, V/F, and F/F).
- Preserves physiological complement activation (CDC baseline).
- Maintains standard FcRn endosomal recycling and in vivo systemic persistence.
Applications
- Therapeutic oncology antibodies targeting cell surface antigens (e.g., CD20, HER2, EGFR).
- Solid tumor therapeutic formats requiring both NK cell killing and macrophage tumor clearance.
- Comparative effector function profiling against DE, DLE, and GASDALIE modules.
- Preclinical development of high-potency depleting antibodies with controlled complement activity.
Plasmid Map & Feature Annotation
Insert Structure: VH – CH1 – hinge(G236A) – CH2(S239D/I332E) – CH3(wild-type)
- VH: Variable heavy domain
- CH1: Constant heavy 1
- Hinge: Native IgG1 core hinge
- Lower Hinge (G236A): FcγRIIa-selective activation mutation
- CH2 (S239D/I332E): ADCC/ADCP-enhancing electrostatic double mutation
- CH3 (WT): Native IgG1 CH3 domain
Product Note: The ADE Fc variant (G236A/S239D/I332E) represents a balanced, multi-mechanistic effector module in the Fusion BioLabs portfolio. By combining the phagocytosis-enhancing properties of G236A with the core electrostatic double mutant DE (S239D/I332E), ADE delivers potent dual ADCC/ADCP enhancement without requiring the structural hydrophobic packing mutation A330L present in GASDALIE.
Fusion BioLabs ADCC/ADCP-Enhanced Family Comparison Matrix
| Variant | Mechanism | Enhancement Strength | Primary Application & Notes |
|---|---|---|---|
| human IgG1 (WT) Wild-Type |
Native baseline FcγR binding | ★★☆☆☆ | Baseline Control. Standard physiological FcγR binding and ADCC/ADCP baseline for comparative assays. |
| human IgG1 (G236A) G236A |
Lower hinge FcγRIIa selective optimization | ★★★☆☆+ | Selective ADCP Enhancer. Specifically boosts macrophage phagocytosis by maximizing the FcγRIIa/FcγRIIb activation ratio. |
| human IgG1 (DE) S239D / I332E |
CH2 domain electrostatic interface enhancement | ★★★☆☆ | Moderate ADCC/ADCP Enhancer. Core double mutation boosting FcγRIIIa and FcγRIIa engagement. |
| human IgG1 (DLE) S239D / A330L / I332E |
CH2 domain structural interface enhancement | ★★★★☆ | Strong ADCC Enhancer. Classic triple mutation optimizing NK cell-mediated lysis. |
| human IgG1 (ADE) G236A / S239D / I332E |
CH2 domain multi-residue FcγRIIIa optimization | ★★★★☆+ | This Product. High-Potency ADCC/ADCP Enhancer. Increases FcγRIIIa binding while improving the FcγRIIa/FcγRIIb binding ratio to favor activation over inhibition. |
| human IgG1 (GASDALIE) G236A / S239D / A330L / I332E |
CH2 domain hyper-enhancement (FcγRIIIa & FcγRIIa) | ★★★★★ | Ultra-Potent ADCC/ADCP Enhancer. Maximum engineered affinity variant for low antigen density targets. |
Storage & Handling
- Store plasmid at −20°C.
- Avoid repeated freeze–thaw cycles.
- Handle using sterile technique.
- Suitable for transient or stable mammalian expression (CHO, HEK293, NS0).
References
- Richards JO, Karki S, Lazar GA, Chen H, Dang W, Dahiyat BI. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther. 2008;7(8):2517-2527.
- Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103(11):4005-4010.
- Ahmed AA, Keremane SR, Vielmetter J, Bjorkman PJ. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa. J Struct Biol. 2016;194(1):78-89.
